Eli Lilly Reports post-marketing Data for Alirocumab in Hepatocellular carcinoma

Eli Lilly today announced post-marketing results for alirocumab in patients with hepatocellular carcinoma. The study demonstrated that alirocumab achieves clinical remission compared to standard of care or placebo. These results provide important insights into the treatment of hepatocellular carcinoma and support the continued development of alirocumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.